Before the U.S. Food and Drug Administrations controversial approval of Biogens Aduhelm (aducanumab) for Alzheimers disease in June 2021, there were well over 200 failed clinical trials in the last twenty years for drugs to treat the disease. Part of the drugs controversy is the alleged negligible improvement in Alzheimers symptoms. At the highest doses, which can be risky, Aduhelm appears to slow the progression of the disease in patients if caught early enough.
Aducanumab is an antibody that clears beta-amyloid in the brain, one of two proteins that accumulate abnormally in the disease. Although beta-amyloid is associated with the disease, its not the only factor, and researchers are making progress on understanding Alzheimer's better and taking new approaches. Heres a look.
Screening Approach to Why Alzheimers Drugs Fail
A team at the University of California, San Diegodeveloped a drug screening method to help determine why Alzheimers drugs fail. The system analyzes disease mechanisms in human neurons. They published their research in Alzheimers & Dementia. The researchers note that sometimes drugs that clear amyloid dont improve the disease but make it worse. With that as the focus, their drug screening method evaluates what endotypes, or disease mechanisms, are modified in the patients neurons from the treatment. They note that although amyloid plaque formation is one endotype, others should be targeted, including differentiation of neurons to an early non-neuron state, neuronal gene suppression and loss of synaptic connection.
The key here is that we are using the endotypes that we discovered to see how current drugs fail, senior author Shankar Subramaniam, Ph.D., said. When drugs interact with human neurons, what endotypes do the drugs fix and what endotypes do they not fix in the process?
Their technique requires taking human-induced pluripotent stem cells derived from patients with familial Alzheimers disease and transforming them into neurons. They then treat these cells with drugs and leverage genetic sequencing to determine what endotypes change pre-and post-treatment. They also do the same on neurons derived from healthy people.
In a test of two experimental Alzheimers drugs targeting amyloid, the researchers found the drugs only improved some endotypes, such as the formation of amyloid plaques, partly fixing some, while not fixing others.
What we are seeing is that fixing amyloid plaque formation does not reverse the disease in any way, Subramaniam said. It turns out that this endotype is way downstream, so it is too late. Once neurons de-differentiate into non-neurons, they lose their synaptic connections, which leads to loss of memory and cognition and as a consequence, dementia.
Targeting Alzheimers Earlier in the Process
Although amyloid and a second protein, tau, are linked to Alzheimers, with amyloid generally occurring earlier and tau later in the disease, some researchers are focused earlier. Qin Wang, MD, Ph.D., with the new Alzheimers Therapeutics Discovery program at the Medical College of Georgia, described amyloid and tau as like a gun in the brain: beta amyloid is the trigger and tau is the bullet. Wang is looking at why and how they interact.
Theres a missing link there, Wang stated.
Earlier in Alzheimers, a group of neurons in a part of the brain called the locus coeruleus seem to die first. Those nerves interact with norepinephrine, a neurotransmitter. Norepinephrine is involved in various processes, including fight or flight, arousal, attention and memory. They have connections throughout the brain and, Wang said, seem to be hypersensitive to amyloid beta and tau.
These cells have a special receptor that can both release, and are involved in receiving norepinephrine. Once turned on, the receptor controls the protein that creates beta amyloid. But once beta amyloid is formed, it can attach to the same receptor in a different location and begin creating more beta amyloid in what Wang describes as a vicious cycle.
This is very important for the initial seeding of the (deposits) in the brain, Wang said.
Wang noted that drugs that target amyloid remove about 60% at best, which isnt nearly enough. Very little beta amyloid is needed to feed the cycle, with even 1% still sufficiently activates this detrimental pathway.
So Wang and her team are evaluating drugs that can prevent that cycle. Two are already on the market. One of them is an approved antidepressant, Idazoxan. Another is a blood pressure medication called clonidine that also activates the particular receptor in the brain.
Hopefully in humans, if we can block those receptors, we will see the oppositive effect, Wang said. We can see an improvement in their cognitive function.
NeuroNascents Neuron Regeneration Drug
NeuroNascent reported data from a Phase I trial of NNI-362 in Alzheimers disease. The drug demonstrated favorable safety and a significant decrease in a biomarker for Alzheimers disease. The drug appears to produce new neurons to replace lost neurons or improve their numbers in aging patients or neurodegenerative diseases, such as Alzheimers.
The drug is taken orally and data showed it to be well tolerated in healthy aged people after single and multiple daily dosing. Using a new test to detective Alzheimers biomarkers in blood plasma, the drug also significantly decreased p-tau181 levels compared to pre-treatment levels.
This exciting early data, demonstrating our novel allosteric oral therapy, NNI-362, can normalize the plasma p-tau181 a biomarker correlated with Alzheimers disease brain pathology and progression, supporting the need to further test NNI-362 in long-term trials, Judith Kelleher-Andersson, Ph.D., founder and chief executive officer of Neuronascent, said. Running of a Phase II trial in mild to moderate Alzheimers disease patients could assess longer-term amelioration of p-tau181 levels and to determine if this intervention could consequently improve quality of life for patient and caregiver.
Read the rest here:
Identifying Missing Links - and Why Certain Drugs Don't Work - in Alzhiemer's - BioSpace
- CIRI calls for safety advice revamp after health concerns raised by 3D printing emission research - 3D Printing Industry - October 13th, 2022
- Global Adult Stem Cells Market | Expected to Reach USD 9.45 Billion and Compound Annual Growth Rate (CAGR) is - openPR - October 4th, 2022
- The cloudy connection between fragile X and cancer - Spectrum - October 4th, 2022
- CBD And CBG Show Promising Results In Treating Glioblastoma Brain Tumors - The Fresh Toast - June 22nd, 2022
- How Protein Nanoparticle Vaccines Have The Potential To Be Developed Into 'Safer' Covid-19 Vaccines: Study - ABP Live - June 4th, 2022
- SpaceX capsule returns to Earth with first all-private space station crew Spaceflight Now - Spaceflight Now - May 2nd, 2022
- Axion BioSystems Acquires Live-Cell Imaging Innovator CytoSMART Technologies - Business Wire - March 25th, 2022
- Avra, Inc. Completes its Merger with Springs Rejuvenation, LLC, a Stem Cell and Anti-Aging Treatment Company - GlobeNewswire - December 24th, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and... - November 8th, 2021
- BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting &... - November 8th, 2021
- Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and... - November 8th, 2021
- MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual... - November 8th, 2021
- Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and... - November 8th, 2021
- Role of Stem Cells in Treatment of Neurological Disorder - October 16th, 2021
- A plant that 'cannot die' reveals its genetic secrets - The Independent - August 5th, 2021
- Exploring science with a new generation of girls - US Embassy in Georgia - February 11th, 2021
- Stemcell Renewal Elixir GEORGIA LOUISE - September 25th, 2020
- COVID is shifting the conversation about the medical application of CBD - Open Access Government - September 22nd, 2020
- Robert E. Windsor, MD, is being recognized by Continental Who's Who - PRNewswire - September 22nd, 2020
- Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer - Yahoo... - June 6th, 2020
- Athens hospital using biologic treatment on COVID-19 patients - Online Athens - June 2nd, 2020
- Study reveals birth defects caused by flame retardant - University of Georgia - June 2nd, 2020
- Novant Health Initiates Phase 2b/3 Trial with CytoDyns Leronlimab for Severely and Critically Ill COVID-19 Patients - Yahoo Finance - May 11th, 2020
- CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -... - May 5th, 2020
- Covid-19 has shuttered labs. It could put a generation of researchers at risk - STAT - May 5th, 2020
- CytoDyn (OTC: CYDY) Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable... - May 5th, 2020
- Stem Cell Therapy in Atlanta, GA - sipapain.com - February 3rd, 2020
- Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trends and Forecast to 2025 - News Distribute - December 27th, 2019
- Transition to exhaustion: clues for cancer immunotherapy - 7thSpace Interactive - December 5th, 2019
- Autologous Stem Cell And Non Stem Cell Based Therapies Market Opportunity Analysis and Industry Forecast up to 2026 - Guru Online News - November 20th, 2019
- Georgia solar factory scores on tariffs; others in industry take a hit - Atlanta Journal Constitution - September 23rd, 2019
- Georgia Stem Cells | Stem Cell TV - September 7th, 2019
- Current Strategies and Challenges for Purification of ... - March 6th, 2019
- Stem Cell Savannah Georgia 31401 - January 20th, 2019
- Atlanta, Georgia Stem Cell Transplant, Marietta, Berkeley ... - September 7th, 2018
- Placenta | Amniotic tissue is not stem cell therapy - Dr ... - July 17th, 2018
- Turning Skin Cells Into Brain Cells - 06/28/2012 - October 1st, 2017
- This Wasp's Larvae Sometimes Grow Hundreds of Soldier ClonesBut Why? - Entomology Today - August 21st, 2017
- Atlanta Stem Cell Therapy | Georgia Stem Cell Treatments ... - October 7th, 2016
- Storing Stem Cells In Teeth For Your Familys Future Health - October 31st, 2015
- Scientists Turn Back the Clock on Adult Stem Cells Aging ... - October 16th, 2015
- Lymphoid Cells, Lymphoid Stem Cells - AllCells.com - October 11th, 2015
- Using Stem Cells in Teeth for Future Use in Developing ... - September 30th, 2015
- Human Mesenchymal Stem Cells & Media - September 25th, 2015
- Asymmetrex Plans to Report Results From Adult Stem Cell ... - August 2nd, 2015
- Stem Cells - Lonza - July 10th, 2015
- Global Stem Cells Group Announces First Stem Cell Training ... - June 3rd, 2015
- Effective Hematopoietic Mesenchymal Stem Cell Therapies - April 25th, 2015
- Stem Cells Hashimoto's Thyroiditis - April 22nd, 2015
- Welcome to Atlanta Stem Cell Treatment - April 9th, 2015
- Stem Cells Thailand - Stem Cell Therapy Thailand - March 27th, 2015
- Stem Cell Institute Los Angeles Chronic Pain Treatments - March 27th, 2015
- Graphene Shows Promise In Eradication Of Stem Cancer Cells - March 10th, 2015
- Stem Cell Treatment India,Stem Cell Treatment India,Cost ... - March 8th, 2015
- Bone Marrow & Stem Cell Transplant Center | Atlanta, GA ... - November 16th, 2014
- Biological fat with a sugar attached essential to maintaining the brain's supply of stem cells - November 3rd, 2014
- How stress ups depression risk - October 21st, 2014
- Protein appears to protect against bone loss in arthritis - September 13th, 2014
- Boron Facilitates Stem Cell Growth and Development in Corn - August 29th, 2014
- Georgia (Stem Cell) - what-when-how - August 26th, 2014
- Stem Cells in GA - Georgia Bio - August 25th, 2014
- Stem Cells COPD | Stem Cell Treatments - August 23rd, 2014
- Stem Cells Atlanta GA, Stem Cell Therapy, Dental Stem Cells - August 22nd, 2014
- Stem cells reveal how illness-linked genetic variation affects neurons - August 22nd, 2014